Day 2Wednesday, September 2, 2026 - UTC+08:00

• Delving into the transformative potential of nucleic acid-based therapies and enabling technologies, with insights into APAC’s unique investment opportunities, including emerging biotech hubs, innovative startups, and regional strengths in clinical trials and manufacturing

• Exploring collaborative investment strategies to accelerate development pipelines and expand market access for nucleic acid technologies across APAC.

• Examining the evolving regulatory frameworks for nucleic acid therapeutics across Asia-Pacific and Western regions, with a focus on harmonizing standards to support global innovation and accessibility.

• Discussing challenges and opportunities in navigating diverse regulatory landscapes, including strategies for accelerating approvals and ensuring safety and efficacy in emerging RNA-based treatments.

• Skin regeneration is governed by the fibroblast–extracellular matrix (ECM) axis, yet current therapies typically act indirectly on fibroblasts and yield limited or short-lived improvements in collagen content and dermal architecture.
• This presentation will discuss how RNA therapeutics can be applied in direct ECM restoration, with a particular focus on advances on trans-amplifying RNA (taRNA) technologies. It will also address current limitations of mRNA drug in regeneration medicine, and describe efforts in her group to further improve mRNA delivery, durability and functionality.

.

• Developing a scalable cell-derived nanoparticle platform for RNA delivery to the brain
• In preclinical animal studies, the platform showed functional RNA delivery to over 70% of neurons following a single IV injection

Highlighting the future innovation potential of RNA therapeutics, focusing on next-generation approaches such as AI-driven RNA design, RNA editing, non-coding RNAs, and circular RNAs (circRNAs) to address complex diseases and advance precision medicine in Asia-Pacific. This panel will explore how artificial intelligence is revolutionizing RNA drug discovery, target identification, and optimization of therapeutic efficacy, accelerating the development of personalized RNA-based treatments.